|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Agarwal G, Pradeep PV, Aggarwal V, Yip CH
and Cheung PS: Spectrum of breast cancer in Asian women. World J
Surg. 31:1031–1040. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
ODriscoll L and Clynes M: Biomarkers and
multiple drug resistance in breast cancer. Curr Cancer Drug
Targets. 6:365–384. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li B, Lu Q, Song ZG, Yang L, Jin H, Li ZG,
Zhao TJ, Bai YF, Zhu J, Chen HZ, et al: Functional analysis of DNA
methylation in lung cancer. Eur Rev Med Pharmacol Sci.
17:1191–1197. 2013.PubMed/NCBI
|
|
5
|
Arrigoni E, Galimberti S, Petrini M,
Danesi R and Di Paolo A: ATP-binding cassette transmembrane
transporters and their epigenetic control in cancer: An overview.
Expert Opin Drug Metab Toxicol. 12:1419–1432. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Yen CY, Huang HW, Shu CW, Hou MF, Yuan SS,
Wang HR, Chang YT, Farooqi AA, Tang JY and Chang HW: DNA
methylation, histone acetylation and methylation of epigenetic
modifications as a therapeutic approach for cancers. Cancer Lett.
373:185–192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kozaki K and Inazawa J: Tumor-suppressive
microRNA silenced by tumor-specific DNA hypermethylation in cancer
cells. Cancer Sci. 103:837–845. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu SL, Sui YF and Lin MZ: MiR-375 is
epigenetically downregulated due to promoter methylation and
modulates multi-drug resistance in breast cancer cells via
targeting YBX1. Eur Rev Med Pharmacol Sci. 20:3223–3229.
2016.PubMed/NCBI
|
|
9
|
Ye XM, Zhu HY, Bai WD, Wang T, Wang L,
Chen Y, Yang AG and Jia LT: Epigenetic silencing of miR-375 induces
trastuzumab resistance in HER2-positive breast cancer by targeting
IGF1R. BMC Cancer. 14:1342014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li X, Wu Y, Liu A and Tang X: MiR-27b is
epigenetically downregulated in tamoxifen resistant breast cancer
cells due to promoter methylation and regulates tamoxifen
sensitivity by targeting HMGB3. Biochem Biophys Res Commun.
477:768–773. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
He DX, Gu XT, Li YR, Jiang L, Jin J and Ma
X: Methylation-regulated miR-149 modulates chemoresistance by
targeting GlcNAc N-deacetylase/N-sulfotransferase-1 in human breast
cancer. FEBS J. 281:4718–4730. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hu H, Li S, Cui X, Lv X, Jiao Y, Yu F, Yao
H, Song E, Chen Y, Wang M, et al: The overexpression of
hypomethylated miR-663 induces chemotherapy resistance in human
breast cancer cells by targeting heparin sulfate proteoglycan 2
(HSPG2). J Biol Chem. 288:10973–10985. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
He DX, Gu XT, Jiang L, Jin J and Ma X: A
methylation-based regulatory network for microRNA 320a in
chemoresistant breast cancer. Mol Pharmacol. 86:536–547. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Xu Q, Jiang Y, Yin Y, Li Q, He J, Jing Y,
Qi YT, Xu Q, Li W, Lu B, et al: A regulatory circuit of
miR-148a/152 and DNMT1 in modulating cell transformation and tumor
angiogenesis through IGF-IR and IRS1. J Mol Cell Biol. 5:3–13.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li JZ, Wang ZL, Xu WH, Li Q, Gao L and
Wang ZM: MicroRNA-495 regulates migration and invasion in prostate
cancer cells via targeting Akt and mTOR signaling. Cancer Invest.
34:181–188. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lee SH, Jung YD, Choi YS and Lee YM:
Targeting of RUNX3 by miR-130a and miR-495 cooperatively increases
cell proliferation and tumor angiogenesis in gastric cancer cells.
Oncotarget. 6:33269–33278. 2015.PubMed/NCBI
|
|
17
|
Xu YY, Tian J, Hao Q and Yin LR:
MicroRNA-495 downregulates FOXC1 expression to suppress cell growth
and migration in endometrial cancer. Tumour Biol. 37:239–251. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cao M, Nie W, Li J, Zhang Y, Yan X, Guan
X, Chen X, Zen K, Zhang CY, Jiang X, et al: MicroRNA-495 induces
breast cancer cell migration by targeting JAM-A. Protein Cell.
5:862–872. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mao Y, Li L, Liu J, Wang L and Zhou Y:
MiR-495 inhibits esophageal squamous cell carcinoma progression by
targeting Akt1. Oncotarget. 7:51223–51236. 2016.PubMed/NCBI
|
|
20
|
Lv C, Bai Z, Liu Z, Luo P and Zhang J:
MicroRNA-495 suppresses human renal cell carcinoma malignancy by
targeting SATB1. Am J Transl Res. 7:1992–1999. 2015.PubMed/NCBI
|
|
21
|
Chen SM, Chen HC, Chen SJ, Huang CY, Chen
PY, Wu TW, Feng LY, Tsai HC, Lui TN, Hsueh C, et al: MicroRNA-495
inhibits proliferation of glioblastoma multiforme cells by
downregulating cyclin-dependent kinase 6. World J Surg Oncol.
11:872013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jiang X, Huang H, Li Z, He C, Li Y, Chen
P, Gurbuxani S, Arnovitz S, Hong GM, Price C, et al: MiR-495 is a
tumor-suppressor microRNA down-regulated in MLL-rearranged
leukemia. Proc Natl Acad Sci USA. 109:pp. 19397–19402. 2012;
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chu H, Chen X, Wang H, Du Y, Wang Y, Zang
W, Li P, Li J, Chang J, Zhao G and Zhang G: MiR-495 regulates
proliferation and migration in NSCLC by targeting MTA3. Tumour
Biol. 35:3487–3494. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Z, Zhang G, Li D, Jie Z, Chen H, Xiong
J, Liu Y, Cao Y, Jiang M, Le Z, et al: Methylation-associated
silencing of miR-495 inhibit the migration and invasion of human
gastric cancer cells by directly targeting PRL-3. Biochem Biophys
Res Commun. 456:344–350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Xu Y, Ohms SJ, Li Z, Wang Q, Gong G, Hu Y,
Mao Z, Shannon MF and Fan JY: Changes in the expression of miR-381
and miR-495 are inversely associated with the expression of the
MDR1 gene and development of multi-drug resistance. PLoS One.
8:e820622013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Song L, Li Y, Li W, Wu S and Li Z: miR-495
enhances the sensitivity of non-small cell lung cancer cells to
platinum by modulation of copper-transporting P-type adenosine
triphosphatase A (ATP7A). J Cell Biochem. 115:1234–1242. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Y and Leung FC: An evaluation of new
criteria for CpG islands in the human genome as gene markers.
Bioinformatics. 20:1170–1177. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Visone R and Croce CM: MiRNAs and cancer.
Am J Pathol. 174:1131–1138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li F and Mahato RI: MicroRNAs and drug
resistance in prostate cancers. Mol Pharm. 11:2539–2552. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Jiang CG, Lv L, Liu FR, Wang ZN, Na D, Li
F, Li JB, Sun Z and Xu HM: Connective tissue growth factor is a
positive regulator of epithelial-mesenchymal transition and
promotes the adhesion with gastric cancer cells in human peritoneal
mesothelial cells. Cytokine. 61:173–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Zang H, Wang W and Fan S: The role of
microRNAs in resistance to targeted treatments of non-small cell
lung cancer. Cancer Chemother Pharmacol. 79:227–231. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen X, Lu P, Wu Y, Wang DD, Zhou S, Yang
SJ, Shen HY, Zhang XH, Zhao JH and Tang JH: MiRNAs-mediated
cisplatin resistance in breast cancer. Tumour Biol. 37:12905–12913.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wang LQ and Chim CS: DNA methylation of
tumor-suppressor miRNA genes in chronic lymphocytic leukemia.
Epigenomics. 7:461–473. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
34
|
Formosa A, Markert EK, Lena AM, Italiano
D, Finazzi-Agro E, Levine AJ, Bernardini S, Garabadgiu AV, Melino G
and Candi E: MicroRNAs, miR-154, miR-299-5p, miR-376a, miR-376c,
miR-377, miR-381, miR-487b, miR-485-3p, miR-495 and miR-654-3p,
mapped to the 14q32.31 locus, regulate proliferation, apoptosis,
migration and invasion in metastatic prostate cancer cells.
Oncogene. 33:5173–5182. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Buettner R, Mora LB and Jove R: Activated
STAT signaling in human tumors provides novel molecular targets for
therapeutic intervention. Clin Cancer Res. 8:945–954.
2002.PubMed/NCBI
|
|
36
|
Song H, Jin X and Lin J: Stat3 upregulates
MEK5 expression in human breast cancer cells. Oncogene.
23:8301–8309. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hiroki E, Suzuki F, Akahira J, Nagase S,
Ito K, Sugawara J, Miki Y, Suzuki T, Sasano H and Yaegashi N:
MicroRNA-34b functions as a potential tumor suppressor in
endometrial serous adenocarcinoma. Int J Cancer. 131:E395–E404.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Fan H, Zhao ZJ, Cheng YC, Shan YF, Lu ZH,
Zhang JQ and Xie W: Gene induction and apoptosis in human
hepatocellular carci-noma cells SMMC-7721 exposed to
5-aza-2-deoxycytidine. Chin Med J (Engl). 120:1626–1631.
2007.PubMed/NCBI
|
|
39
|
Deng H, Guo Y, Song H, Xiao B, Sun W, Liu
Z, Yu X, Xia T, Cui L and Guo J: MicroRNA-195 and microRNA-378
mediate tumor growth suppression by epigenetical regulation in
gastric cancer. Gene. 518:351–359. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bhat TA, Nambiar D, Tailor D, Pal A,
Agarwal R and Singh RP: Acacetin inhibits in vitro and in vivo
angiogenesis and downregulates Stat signaling and VEGF expression.
Cancer Prev Res (Phila). 6:1128–1139. 2013. View Article : Google Scholar : PubMed/NCBI
|
